Merus (NASDAQ:MRUS) Receives $85.31 Average PT from Analysts

Merus (NASDAQ:MRUS) has earned a consensus rating of “Buy” from the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Fourteen investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $85.31.

A number of brokerages recently weighed in on MRUS. The Goldman Sachs Group began coverage on Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 price objective on the stock. Citigroup lifted their price target on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Needham & Company LLC dropped their price target on Merus from $85.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. William Blair reaffirmed an “outperform” rating on shares of Merus in a research report on Friday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price target on shares of Merus in a research report on Monday, March 3rd.

Merus Price Performance

MRUS opened at $47.10 on Thursday. The business has a 50-day moving average of $42.90 and a 200-day moving average of $46.34. Merus has a fifty-two week low of $37.77 and a fifty-two week high of $61.61. The company has a market capitalization of $3.25 billion, a PE ratio of -11.92 and a beta of 1.15.

Merus (NASDAQ:MRUS) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $9.14 million for the quarter, compared to the consensus estimate of $10.57 million. On average, equities research analysts expect that Merus will post -3.85 earnings per share for the current fiscal year.

Institutional Trading of Merus

Several institutional investors have recently bought and sold shares of MRUS. State of Wyoming acquired a new stake in Merus in the 4th quarter valued at $48,000. Wells Fargo & Company MN boosted its stake in Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 300 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Merus in the 4th quarter valued at $60,000. Avior Wealth Management LLC acquired a new stake in Merus in the 4th quarter valued at $76,000. Finally, Lazard Asset Management LLC acquired a new stake in Merus in the 4th quarter valued at $84,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.